ArticleUrologie (Heidelberg, Germany)2025
[Specialized ambulatory palliative care for urological tumors].
Article in Urologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bridging urology and palliative care: a narrative review of current practice and evolving priorities.Current opinion in urology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrologic tumors comprise about 20% of cancer diagnoses in Germany. To date, there are no studies with large datasets on the palliative situation of patients with urological tumors in the home environment, although dignified end-of-life care in the home environment is the wish of most cancer patients.
methodsData from 5125 patients who received specialized outpatient palliative care (SAPV) with an underlying urological cancer between 2017 and 2021 were included in the analysis.
resultThe analysis showed that 91.5% of patients died at home and the symptom burden remained stable or decreased slightly during treatment. The median survival time of patients receiving SAPV was 24 days. Factors such as age, performance status, loss of appetite, weakness, and pain at the start of treatment influenced the survival time of the patients. Relatives were largely very satisfied with the care provided.
conclusionThe study provides important insights into the palliative care of patients with urological tumors and underlines the importance of SAPV for dignified end-of-life care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.